Skip to content
10-Q

Quarterly Report

NORTHWEST BIOTHERAPEUTICS INC NWBO

0001410578-24-001278

← back to feed
Filed
Aug 9, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 6, 2024 1.25B sh
Long Term Debt Q2 2024 · Jun 30, 2024 $51.04M
Long Term Debt Q2 2024 · Dec 31, 2023 $40.79M
Cash And Equivalents Q2 2024 · Jun 30, 2024 $2.88M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $2.13M
Current Liabilities Q2 2024 · Jun 30, 2024 $56.17M
Current Liabilities Q2 2024 · Dec 31, 2023 $45.2M
Total Liabilities Q2 2024 · Jun 30, 2024 $85.97M
Total Liabilities Q2 2024 · Dec 31, 2023 $74.92M
Current Assets Q2 2024 · Jun 30, 2024 $4.98M
Current Assets Q2 2024 · Dec 31, 2023 $4.13M
Total Assets Q2 2024 · Jun 30, 2024 $28.23M
Total Assets Q2 2024 · Dec 31, 2023 $27.87M
Shares Diluted Q2 2024 · Jun 30, 2023 1.11M sh
Shares Diluted Q2 2024 · Jun 30, 2023 1.09M sh
Capex Q2 2024 · Jun 30, 2023 $2.58M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$22.76M
Stockholders Equity Q2 2024 · Jun 30, 2023 −$61.03M
Stockholders Equity Q2 2024 · Mar 31, 2023 −$55.98M
Stockholders Equity Q2 2024 · Dec 31, 2022 −$128.1M
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.01
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.02
Eps Basic Q2 2024 · Jun 30, 2023 −$0.01
Eps Basic Q2 2024 · Jun 30, 2023 −$0.02
Sga Expense Q2 2024 · Jun 30, 2023 $7.56M
Sga Expense Q2 2024 · Jun 30, 2023 $14.55M
Rd Expense Q2 2024 · Jun 30, 2023 $6.21M
Rd Expense Q2 2024 · Jun 30, 2023 $13.08M
Net Income Q2 2024 · Jun 30, 2023 −$14.45M
Net Income Q2 2024 · Jun 30, 2023 −$25.1M
Operating Income Q2 2024 · Jun 30, 2023 −$13.58M
Operating Income Q2 2024 · Jun 30, 2023 −$26.54M
Revenue Q2 2024 · Jun 30, 2023 $201K
Revenue Q2 2024 · Jun 30, 2023 $1.08M